share_log

We Think That There Are More Issues For Shanghai OPM Biosciences (SHSE:688293) Than Just Sluggish Earnings

We Think That There Are More Issues For Shanghai OPM Biosciences (SHSE:688293) Than Just Sluggish Earnings

我們認爲上海浦申生物(SHSE:688293)面臨的問題不僅僅是收益疲軟。
Simply Wall St ·  09/06 18:11

Shanghai OPM Biosciences Co., Ltd.'s (SHSE:688293) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying factors which may be of concern.

上海OPm生物科技有限公司(SHSE:688293)最近的低收益報告並沒有引起股票大幅動盪。然而,我們認爲投資者應該注意一些潛在因素,可能引起關注。

big
SHSE:688293 Earnings and Revenue History September 6th 2024
SHSE:688293盈利和營業收入歷史數據 2024年9月6日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

To properly understand Shanghai OPM Biosciences' profit results, we need to consider the CN¥6.0m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Shanghai OPM Biosciences had a rather significant contribution from unusual items relative to its profit to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

要正確理解上海OPm生物科技的利潤結果,我們需要考慮到600萬人民幣非常規項目所帶來的收益。雖然我們喜歡看到利潤增長,但當非常規項目做出巨大貢獻時,我們往往會更加謹慎。當我們分析全球絕大多數上市公司時,我們發現重要的非常規項目通常不會重複出現。畢竟,這也是會計術語的含義。與2024年6月的利潤相比,上海OPm生物科技非常規項目的貢獻相當顯著。其他條件不變的情況下,這可能導致法定利潤成爲判斷基本盈利能力的不良指標。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Shanghai OPM Biosciences' Profit Performance

我們對上海OPm生物科技的盈利表現的看法

As previously mentioned, Shanghai OPM Biosciences' large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Shanghai OPM Biosciences' underlying earnings power is lower than its statutory profit. Sadly, its EPS was down over the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. At Simply Wall St, we found 2 warning signs for Shanghai OPM Biosciences and we think they deserve your attention.

正如先前提到的,上海OPm生物科技公司由於飛凡項目的大幅提升,其非常規項目對其收益的巨大影響不會無限期持續下去,因此其法定收益可能並不是衡量其潛在盈利能力的良好指標。因此,我們認爲上海OPm生物科技公司的潛在盈利能力很可能低於其法定利潤。遺憾的是,其每股收益在過去的十二個月中有所下降。最終,如果您想要正確地了解公司,必須考慮不僅僅是上述因素。因此,如果您希望對該公司進行更多分析,了解相關風險是至關重要的。在Simply Wall St,我們發現上海OPm生物科技公司有2個警示信號,我們認爲這值得您的關注。

This note has only looked at a single factor that sheds light on the nature of Shanghai OPM Biosciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

這篇筆記只是簡單探討了揭示上海OPm生物科技公司利潤本質的單一因素。但如果你有能力集中注意力關注細微之處,總是會有更多發現。有些人認爲高股權回報率是質量好的企業的良好標誌。因此,您可能希望查看擁有高股權回報率的公司的免費收藏,或者查看這份擁有高內部持股的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論